SERUM-SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS BEFORE AND AFTER SURGICAL-TREATMENT FOR GRAVES-DISEASE

被引：5

作者：

MURAKAMI, S ^{[1
]}

KOBAYASHI, A ^{[1
]}

KUMA, K ^{[1
]}

MURAI, H ^{[1
]}

OKAMURA, Y ^{[1
]}

SATOMI, A ^{[1
]}

ISHIDA, K ^{[1
]}

机构：

[1] KUMA HOSP,CHUO KU,KOBE,HYOGO 650,JAPAN

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1995年 / 25卷 / 01期

关键词：

INTERLEUKIN-2; RECEPTOR; GRAVES DISEASE; TRAB;

D O I：

10.1007/BF00309386

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Serum-soluble interleukin-2 receptor (ssIL-2R) is released from its specific affinity membrane receptor on activated T lymphocytes and is detected as a form of the alpha-chain of IL-2R in the peripheral blood. We measured the ssIL-2R levels by enzyme-linked immunosorbent assay in 29 healthy subjects and 39 patients with Graves' disease who were given antithyroid drugs to prepare them for surgical treatment. The preoperative ssIL-2R levels in Graves' patients were significantly higher than those in the healthy controls (681 +/- 387 vs 369 +/- 149 U/ml); in particular, the preoperative levels in hyperthyroid patients were significantly higher than those in euthyroid patients. On the 5th day after thyroid resection, their ssIL-2R levels (560 +/- 296 U/ml) were significantly lower than the preoperative levels. There were no correlations between the preoperative ssIL-2R levels and the immunological parameters such as thyroglobulin antibody, microsomal antibody, and thyroid-stimulating hormone receptor antibody. Thus, we conclude that ssIL-2R levels can be decreased by surgical resection of goiter in Graves' patients whose hyperthyroid status does not respond to the administration of antithyroid drugs, and this may be a useful indicator of immunological status after surgical treatment of Graves' disease.

引用

页码：55 / 58

页数：4

共 21 条

[1]

Smith K.A., Interleukin-2, inception, impact and implications, Science, 240, (1988)

[2]

Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson D.L., Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro, J Immunol, 135, pp. 3172-3177, (1985)

[3]

Symons J.A., Wod N.C., Di Giovine F.S., Duff G.W., Soluble IL-2 receptor in rheumatoid arthritis: correlation with disease activity, IL-1 and IL-2 inhibition, J Immunol, 141, pp. 2612-2618, (1988)

[4]

Yamaguchi K., Nishimura Y., Kiyokawa T., Matsuzaki H., Ishii T., Kubota K., Kawahara M., Furuse K., Yoshinaga T., Kinuwaki E., Takatsuki K., Elevated serum levels of soluble interleukin 2 receptors in small cell lung carcinoma, J Lab Clin Med, 116, pp. 457-461, (1990)

[5]

Pui C.H., Ip S.H., Iflah S., Behm F.G., Grose B.H., Dodge R.K., Crist W.M., Furman W.L., Murphy S.B., Rivera G.K., Serum Interleukin 2 receptor levels in childhood acute lymphoblastic leukemia, Blood, 71, pp. 1135-1137, (1988)

[6]

Honda M., Kitamura K., Matsuda K., Yokota Y., Yamamoto N., Mitsuyasu R., Chermann J.C., Tokunaga T., Soluble IL-2 receptor in AIDS, J Immunol, 142, pp. 4248-4255, (1989)

[7]

Weryha G., Gobert B., Leclere J., Bene M.C., Faure G., Hartemann P., Dynamic changes in soluble interleukin-2 receptor levels during treatment of Graves' disease, Horm Res, 35, pp. 8-12, (1991)

[8]

Mariotti S., Caturegli P., Barbesino G., Prete G.F.D., Chiovato L., Pinchera A., Circulating soluble interleukin-2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism, J Endocrinol Invest, 14, pp. 777-781, (1991)

[9]

Chow C.C., Lai K.N., Leung J.C.K., Chan J.C.N., Cockram C.S., Serum soluble interleukin-2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy, Clin Endocrinol, 33, pp. 317-321, (1990)

[10]

Balazs C.Z., Farid N.R., Soluble interleukin-2 receptor in sera of patients with Graves' diseases, J Autoimmun, 4, pp. 681-688, (1991)

← 1 2 3 →